Insight

Bishal Gyawali: This is why we need randomized controlled trials

Bishal Gyawali/scri.queensu.ca

Feb 11, 2025, 08:55

Bishal Gyawali: This is why we need randomized controlled trials

Bishal Gyawali, Associate Professor at Queen’s University, Kingston, shared a post on X about a recent paper by Amit Oza et al. published in The Lancet Oncology:

“Wow, this is why we need RCTs. Patients in the experimental arm had 6 months shorter survival than patients in the control arm. Statistically significant. But guess what the conclusion is?

Why can’t we say that this drug shortened OS and shouldn’t be used? The medical writer who wrote this conclusion should get a raise.

It is this type of reporting that we aim to avoid by using the CSO checklist.”

“Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial”

Authors: Amit Oza, Alla Lisyanskaya, Alexander Fedenko, Sandra Goble, Rebecca Kristeleit et al.

Bishal Gyawali: This is why we need randomized controlled trials

More posts featuring Bishal Gyawali.

Alexander Fedenko Alla Lisyanskaya Amit Oza Bishal Gyawali cancer OncoDaily Oncology Randomized Controlled Trials RCTs Rebecca Kristeleit Sandra Goble

Mesothelioma Guideline Updates from ASCO 2024: Key Advances in Diagnosis and Treatment

Oncologist Near Me - Lynn Schuchter: A Pioneering Leader in Cancer Care and Melanoma Research

NIH lowered the maximum indirect cost rate research institutions can charge the government to 15%

Stanley Tucci and Throat Cancer: How He Went Against, How He Survived, and More

Senator John Fetterman Responds to OncoDaily on Pediatric Oncology Funding